Skip to content
DataLookout
Menu

ESKRAPNCT07949500

Esketamine Plus Sirolimus for Adults With Depression Who Have Not Responded to Esketamine

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 5
Timeframe: Baseline (Week 1, before the first study dose) and Week 5 (7 days after the last esketamine infusion)

Secondary (19)

Percentage of Participants With Depression Response
Percentage of Participants With at Least Partial Depression Response
Percentage of Participants With Depression Remission
Percentage of Participants With a MADRS Total Score Below 19
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) Total Score
Show 14 moreShow less
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score
Clinical Global Impression-Improvement (CGI-I) Score
Change in MADRS Total Score From Week 5 During Follow-Up
Time to Depression Relapse Among Week 5 Responders
Change From Baseline in Generalized Anxiety Disorder-7 (GAD-7) Total Score
Change From Baseline in Brazilian Snaith-Hamilton Pleasure Scale (SHAPS-BR) Total Score
Change From Baseline in Seven-Item Beck Hopelessness Scale (BHS-7) Total Score
Change From Baseline in Brief Pittsburgh Sleep Quality Index (B-PSQI) Total Score
Percentage of Week 5 Responders Meeting Depression Response Criteria at Follow-Up
Change From Baseline in SF-12 Physical Component Summary Score
Change From Baseline in SF-12 Mental Component Summary Score
Change From Baseline in SF-6D Health Utility Index
Suicidal Ideation and Suicidal Behavior
Altman Self-Rating Mania Scale (ASRM) Total Score

Arms and interventions

Intravenous Esketamine Plus Oral SirolimusExperimental

Participants receive intravenous esketamine 0.375 mg/kg infused over 40 minutes twice weekly for 4 weeks, for a total of eight infusions. Oral sirolimus 6 mg, administered as three 2 mg tablets, is given under direct observation approximately 2 hours before the first esketamine infusion of each week, for a total of four doses. No additional sirolimus dose is given before the second infusion of the week. Participants are followed for 8 weeks after the treatment period.

Drugs: Esketamine, Sirolimus (RAPAMUNE)

Sites

2 sites in 1 country